Ryan Commiskey, NP-C
Nurse Practitioners (Nurse Practitioner)
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 263
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nurse Practitioner primary
NM license CNP-03432
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus St Vincent Regional Medical Center Santa Fe, NM
- Holy Cross Hospital A Div of Taos Health Systems Taos, NM
- Los Alamos Medical Center Los Alamos, NM
Medical groups
- Nexus Health (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 263
- Services billed
- 1,432
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, aprepitant, 1 mg | 3,250 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 566 | 23 |
| Injection, palonosetron hcl, 25 mcg | 510 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 464 | 169 |
| Injection, granisetron hydrochloride, 100 mcg | 300 | 12 |
| Injection, fluorouracil, 500 mg | 248 | 11 |
| Injection of additional new drug or substance into vein | 196 | 34 |
| Administration of chemotherapy into vein, 1 hour or less | 105 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 50 | 47 |
| Administration of chemotherapy into vein, each additional hour | 31 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Santa Fe, NM | 38 |
| Acyclovir Other prescribers in Santa Fe, NM | 23 |
| Prednisone Other prescribers in Santa Fe, NM | 22 |
| Dexamethasone Other prescribers in Santa Fe, NM | 20 |
| Lorazepam Other prescribers in Santa Fe, NM | 16 |
| Oxycodone Hcl Other prescribers in Santa Fe, NM | 14 |
| Ondansetron Odt (ondansetron) Other prescribers in Santa Fe, NM | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 50 companies reported 199 payments worth $4,596 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,234 |
|---|---|
| Janssen Biotech, Inc. | $256 |
| AbbVie Inc. | $204 |
| AstraZeneca Pharmaceuticals LP | $201 |
| Daiichi Sankyo Inc. | $201 |
| Celgene Corporation | $193 |
| Merck Sharp & Dohme LLC | $174 |
| E.r. Squibb & Sons, L.l.c. | $159 |
| Food and Beverage | $3,798 |
|---|---|
| Long term medical supply or device loan | $798 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.